Compare TG Therapeutics Inc (TGTX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Williams Companies Inc — how do they compare? TG Therapeutics Inc trades at $55 (market cap $8.16B), while Williams Companies Inc trades at $72.85 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 10.8× TG Therapeutics Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Williams Companies Inc for 58 Days on average.
| TGTX | WMB | |
|---|---|---|
Market Cap | $8.16B | $88.48B |
Volume | 1,735,121 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $59.06 | $79.40 |
52-Week Low | $26.94 | $56.51 |
Typical Hold Time | 16 Days | 58 Days |
Enterprise Value | $8.37B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Williams Companies (WMB) trades at $72.67, up 1.69% today, with strong analyst support (79% buy ratings) and a consensus price target of $87.27. The stock shows bullish technical signals with support at $72 and resistance at $73. Fundamentally, WMB delivered $11.95B revenue in 2025 with 25.18% net income margin, though recent quarterly earnings were mixed with one beat and two misses. The company benefits from stable fee-based revenues in the midstream energy sector.
WMB presents a compelling opportunity with dividend growth potential and exposure to rising natural gas demand from data centers. However, investors face risks from energy market volatility and high debt levels. The stock trades at a premium valuation (P/E 28.82) but offers 3% dividend yield with consistent payout increases. Near-term catalysts include Q3 earnings and AI-driven power demand growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
